Revvity, Inc. (RVTY)

FairStock Score: 31/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn high returns on capital and trade at a sensible price. Revvity sells instruments, reagents, software, subscriptions and diagnostic tests; that mix can be sticky, but the numbers show only a modest edge so far. In fiscal Q2 2026, the quarter ended 2026-07-05, revenue was $729.7M and net income $51.8M, or $0.47 diluted EPS, versus $720.3M revenue, $53.9M net income and $0.46 EPS in fiscal Q2 2025. Revenue rose about 1.3%, while net income fell about 3.9%. For FY2025, revenue was $2.9B, net income $241.2M and EPS $2.07; FY2024 net income was $270.4M and EPS $2.20, and FY2023 net income was $693.1M and EPS $5.55. That is not a compounding profit stream. FairStock's Lynch category is SLOW GROWER — Shrinking, based on five-year profit decline of 19.8% a year and revenue growth of 1.4%. Financial health looks better than the earnings trend: FairStock's Piotroski F-score is 9/9, Altman Z-score 3.11, D/E 0.46, and trailing FCF is $558.1M. But ROE of 3.21% and ROCE of 2.37% are low. At the $160.39 close on 2026-10-26, P/E is 77.11, P/B 2.48, EV/EBITDA 27.12 and FCF yield 3.1%; the Graham Number is $55.06, a -188.36% margin of safety. I see a fair business with weak profit momentum and a price that already assumes a lot.

In plain English: Revvity sells scientific instruments, tests, software and services used in health research and diagnostics. Overall, the business looks only moderately strong: it is profitable and generates cash, but profit has been uneven and the latest quarter's net income was slightly below a year earlier. At $160.39 on 2026-10-26, the shares look expensive compared with the company's recent earnings and asset value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-07-05) · fiscal Q1 2026 10-Q (period ended 2026-04-05) · fiscal Q3 2025 10-Q (period ended 2025-09-28) · fiscal Q2 2025 10-Q (period ended 2025-06-29) · FY2025 10-K (period ended 2025-12-28) · FY2024 10-K (period ended 2024-12-29) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer